B7-33 exhibits potent anti-fibrotic effects. It is under active research and investigation to reduce fibrosis in acute and chronic diseases like heart failure, lung inflammation, kidney, and more.
In animal studies, B7-33 has reduced fibrosis by roughly 50%, leading to prolonged survival following injury and offering the first new means of treating heart failure in 20 years.
It has been shown to reduce excessive scar formation following cardiac injury. It has also shown promise in the treatment of certain vascular disorders and preeclampsia of pregnancy.
It is occasionally known by: B7-33, GTPL 9321 / Serelaxin Derivative / (B7-33)H2 / RLN2 Derivative / GTPL-9321 / H2 & H3 Relaxin Protein Derivative / B7-33 H2 / Insulin-Like Peptide 3 & 5 Derivative / GTPL9321
Unit Size: 2mg
Catalogue number: B7-33
UK-Peptides Products are sold strictly for research purposes only. Please do not ask about human consumption as this is forbidden.
|Physical and chemical properties|
|Physical Appearance||white lyophilised solid|
|Form & Formulations||Sterile filtered white lyophilized (freeze-dried)|
|Storage||Lyophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18°C. Upon reconstitution of the peptide it should be stored at 4°C between 2-21 days and for future use below -18°C.|
|HPLC||Shows min 99% Purity|
|Mass Spectrum||Consistent with structure|
|Caution||Research use only / Not for human or veterinary use|
All products listed and provided through UK Peptides are intended for research purposes only. We do not promote the personal use of these products.
Products provided by UK Peptides are not intended for use in food products or as any type of drug. Our products are not intended to treat, prevent, mitigate or cure any disease or medical condition and are for research purposes only.